<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">646491</article-id><article-id pub-id-type="doi">10.17816/onco646491</article-id><article-id pub-id-type="edn">UFCPUJ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Features of recurrence of basal cell carcinoma of the scalp</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности рецидивирования базальноклеточного рака кожи головы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1899-554X</contrib-id><name-alternatives><name xml:lang="en"><surname>Ermakova</surname><given-names>Tatiana S.</given-names></name><name xml:lang="ru"><surname>Ермакова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ermakova.ts@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2105-2251</contrib-id><contrib-id contrib-id-type="spin">1065-4191</contrib-id><name-alternatives><name xml:lang="en"><surname>Topuzov</surname><given-names>Eldar E.</given-names></name><name xml:lang="ru"><surname>Топузов</surname><given-names>Эльдар Эскендерович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>eltop@inbox.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8641-1489</contrib-id><name-alternatives><name xml:lang="en"><surname>Ershov</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Ершов</surname><given-names>Владимир Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>ershov415@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2221-4088</contrib-id><contrib-id contrib-id-type="spin">6735-6556</contrib-id><name-alternatives><name xml:lang="en"><surname>Kutukova</surname><given-names>Svetlana I.</given-names></name><name xml:lang="ru"><surname>Кутукова</surname><given-names>Светлана Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>dr.s.kutukova@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">City Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="kk"></institution></aff><aff><institution xml:lang="pt"></institution></aff><aff><institution xml:lang="ru">Городской клинический онкологический диспансер, Санкт-Петербург</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Clinical Oncology Dispensary</institution></aff><aff><institution xml:lang="ru">Городской клинический онкологический диспансер, Санкт-Петербург</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-09-10" publication-format="electronic"><day>10</day><month>09</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-10-19" publication-format="electronic"><day>19</day><month>10</month><year>2025</year></pub-date><volume>30</volume><issue>2</issue><issue-title xml:lang="en">Russian Journal of Oncology</issue-title><issue-title xml:lang="ru">Российский онкологический журнал</issue-title><fpage>124</fpage><lpage>132</lpage><history><date date-type="received" iso-8601-date="2025-01-21"><day>21</day><month>01</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-10-08"><day>08</day><month>10</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-10-19"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/646491">https://rjonco.com/1028-9984/article/view/646491</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold><bold>: </bold>Basal cell carcinoma (BCC) is the most common malignant neoplasm in humans. The cause of local recurrence after radical treatment remains unknown.</p> <p><bold>AIM</bold><bold>: </bold>The work aimed to identify prognostically significant factors for the development of recurrent basal cell carcinoma of the skin.</p> <p><bold>METHODS</bold><bold>: </bold>Study involved 100 patients. We analyzed clinicopathological data from 100 cases of BCC, including 50 cases of newly diagnosed basal cell carcinoma of the scalp and 50 cases with recurrent disease. The recurrence of basal cell carcinoma of the scalp and a primary skin tumor were investigated by histological examination. For this work we used the material obtained after treatment of patients.</p> <p><bold>RESULTS</bold><bold>: </bold>The incidence of BCC recurrence on the nose was four times higher compared to other localizations. Recurrence on the nasal skin occurred in 21 cases; in 29 patients, recurrence was observed when BCC was localized on the skin of the scalp (<italic>n</italic> = 3), auricle (<italic>n</italic> = 3), frontal (<italic>n</italic> = 4), periorbital (<italic>n</italic> = 8), temporal (<italic>n</italic> = 2), buccal (<italic>n</italic> = 7), zygomatic (<italic>n</italic> = 1), and lip areas (<italic>n</italic> = 1). Recurrence of BCC in the frontal area was detected 24 months after treatment; with a tumor infiltration depth of 15.1–20 mm, recurrence occurred at 36 months; in the multicentric variant of BCC, recurrence was noted at 24 months postoperatively.</p> <p><bold>CONCLUSION</bold><bold>: </bold>Diagnostic criteria for BCC recurrence may include localization on the nasal skin, multicentric BCC, BCC originating from skin adnexa, and an infiltration depth of 15.1–20 mm.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Базальноклеточный рак кожи (БКРК) — наиболее часто встречающееся злокачественное новообразование у человека. Причина возникновения его местных рецидивов после радикально проведённого лечения до сих пор остаётся неизвестной.</p> <p><bold>Цель. </bold>Выявление прогностически значимых факторов развития рецидивирования базальноклеточного рака кожи.</p> <p><bold>Методы. </bold>В исследовании принимали участие 100 пациентов. Выполнено исследование клинико-морфологических данных 100 случаев БКРК, из которых 50 — с впервые выявленным базальноклеточным раком кожи головы и 50 — с его рецидивным течением. Рецидив БКРК головы и наличие первичной опухоли кожи, фиксировали проведением гистологического исследования. В работе использовали материал, полученный после лечения.</p> <p><bold>Результаты. </bold>Возникновение рецидива БКРК на носу в 4 раза выше по сравнению с другими локализациями. Рецидив в области кожи носа возник в 21 случае, у 29 пациентов рецидив возник при локализации БКРК на коже волосистой части головы (<italic>n</italic>=3), ушной раковины (<italic>n</italic>=3), лобной (<italic>n</italic>=4), окологлазничной (<italic>n</italic>=8), височной (<italic>n</italic>=2), щёчной (<italic>n</italic>=7), скуловой области (<italic>n</italic>=1) и на коже губ (<italic>n</italic>=1). Наступление рецидива БКРК на коже лобной области выявили спустя 24 месяца, при глубине опухолевой инфильтрации 15,1–20 мм — через 36 месяцев, при мультицентрическом варианте БКРК — через 24 месяца после операции.</p> <p><bold>Заключение. </bold>Диагностически значимыми критериями рецидивирования БКРК могут служить локализация базальноклеточного рака кожи в области носа, мультицентрическая форма БКРК и БКРК из придатков кожи, глубина инфильтрации БКРК от 15,1 до 20 мм.</p></trans-abstract><kwd-group xml:lang="en"><kwd>basal cell carcinoma</kwd><kwd>recurrent basal cell carcinoma</kwd><kwd>predictors of basal cell carcinoma recurrence</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>базальноклеточный рак кожи</kwd><kwd>рецидивное течение базальноклеточного рака кожи</kwd><kwd>предикторы рецидива базальноклеточного рака кожи</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Verkouteren JAC, Ramdas KHR, Wakkee M, NijstenT. Epidemiology of basal cell carcinoma: scholarly review. British Journal of Dermatology. 2017;177(2):359–372. doi: 10.1111/bjd.15321 EDN: YEBMMU</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Nikiforova PO. Comparative clinical-morphological characteristics of basal cell and squamous cell skin cancer. Russian military medical academy reports. 2019;38(S1–2):31–34. EDN: HXFMAI</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kubanov AA, Kondrakhina IN, Plakhova KI, Saitburkhanov RR. Modern understanding of the pathogenesis of basal cell skin cancer. Bulletin of Dermatology and Venereology.2021;97(5):38–51. doi: 10.25208/vdv1277 EDN: QHSTPY</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Fijałkowska M, Bonczar M, Jastrzębski I, et al. Growth rate of basal cell carcinoma: a meta-analysis and systematic review. Postepy Dermatol Alergol. 2023;40(2):220–224. doi: 10.5114/ada.2023.124795 EDN: KCZDHB</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Shulaev AV, Zaripova RN, Zhaboeva SL. Prevalence of risk factors for skin cancer and their management (literature review). Public health and health care. 2020;(2);11–17. EDN: PCKOSE</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cameron MC, Lee E, Hibler BP, et al. Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. Journal of the American Academy of Dermatology.2019;80(2):303–317. doi: 10.1016/j.jaad.2018.03.060 EDN: JNEWEP</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Balakhonov SI, Jordanishvili AK. Age-related features of prevalence, localization and clinical course of some forms of basal cell skin cancer of the face and head. Advances in Gerontology. 2015;28(1):140–145. EDN: TMIYBZ</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zamoresva AA. Analysis of the most common localization of basal cell carcinoma in men and women. Internauka. 2019;(16):18–19. EDN: FNRHJK</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Snarskaya ES, Ibrahim A. Superficial form of basal cell carcinoma of the skin: biological behavior, morphology and clinical variants. Russian Journal of Skin and Venereal Diseases. 2017;20(6):332–341. doi: 10.18821/1560-9588-2017-20-6-332-341 EDN: XNSTFR</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Tarasenko GN, Kolenko NG, Tarasenko YuG. Basal cell skin cancer: modern clinical and diagnostic features and the role of early diagnosis. Russian Journal of Skin and Venereal Diseases.2020;23(1):12–16. doi: 10.17816/dv2020112-16 EDN: DXPPLC</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chuprov IN. Clinical and morphological characteristics of different types of growth of basal cell skin cancer. Bulletin of the St. Petersburg University. Medicine. 2009;(1):145–150. EDN: KVNIVL</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chuprov IN, Novitskaya TA. Morphological markers of the evolution of basal cell skin cancer. Bulletin of St. Petersburg University. Medicine. 2010;(4):116–123. EDN: NDLDNB</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pustynsky IN,Paches AI, Kropotov MA. Remote results of cryodestruction of basal cell carcinoma of the scalp stage II. Russian journal of oncology. 2013;(5):27–30. EDN: RSUFOF</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Gaidina TA, Dvornikov AS, Patsap OI, et al. Primary and multiple malignant skin tumors: melanoma and basal cell carcinoma. Bulletin of Dermatology and Venereology. 2023;99(2):48–62. doi: 10.25208/vdv1415 EDN: HYLBKJ</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Panova IE, Suslo IS, Kuchenkova IA, Arakelyan AE. Peculiarities of the course of basal cell skin cancer with primary-multiple lesion natur. Kazan Medical Journal. 2013;94(4):568–571. EDN: QZIOOH</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kaprin AD, Starinsky VV, Shakhzadova AO, editors. Malignant Neoplasms in Russia in 2021 (Incidence and Mortality). Moscow: P.A. Herzen Moscow Research Institute of Oncology, branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; 2022. 252 p. (In Russ.)</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Komyakevich VV. Retrospective analysis of the results of surgical treatment of basal cell carcinoma. In: Actual Issues of Radiation and Environmental Medicine, Radiation Diagnostics, and Radiation Therapy: Collection of Materials of the VI Interuniversity Scientific and Practical Internet Conference of Students, Magisters, Postgraduate Students, and Young Scientists, Grodno, March 30, 2022. Grodno: Grodno State Medical University; 2022. Р. 157–160. (In Russ.) EDN: NVJABQ</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Titov KS, Mikheeva OYu, Krasnorutsky AV. Malignant Epithelial Tumors of the Skin: Guidelines. Moscow: Department of Health; 2019. 36 p. (In Russ.) EDN: NDEIBK</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Apalla Z, Lallas A, Sotiriou E, et al. Epidemiological trends in skin cancer. Dermatol Pract Concept. 2017;7(2):1–6. doi: 10.5826/dpc.0702a01</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kabanova MA, Volgin VN, Popov NM, Sachek OI, Shelepova EA. Clinical manifestations of basal cell skin cancer and the effectiveness of treatment of patients. Current problems of health care and medical statistics. 2018;(2):28–36. EDN: XSCEVV</mixed-citation></ref></ref-list></back></article>
